Aquestive Therapeutics, Inc. Operating Lease Cost
Aquestive Therapeutics, Inc. (AQST) reported Operating Lease Cost of $558.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-11
- Aquestive Therapeutics, Inc. operating lease, cost for the quarter ending 2026-06-30 was $558.00K, a 22.10% increase year-over-year.
- Aquestive Therapeutics, Inc. operating lease, cost for the quarter ending 2026-03-31 was $447.00K, a 4.68% increase year-over-year.
- Aquestive Therapeutics, Inc. operating lease, cost for the quarter ending 2025-12-31 was $448.00K, a 4.48% decline year-over-year.
- Aquestive Therapeutics, Inc. operating lease, cost for the quarter ending 2025-09-30 was $451.00K, a 1.31% decline year-over-year.
- Aquestive Therapeutics, Inc. operating lease, cost for fiscal 2025 was $1.78M, a 1.71% decline from fiscal 2024.
- Aquestive Therapeutics, Inc. operating lease, cost for fiscal 2024 was $1.81M, a 3.95% increase from fiscal 2023.
- Aquestive Therapeutics, Inc. operating lease, cost for fiscal 2023 was $1.75M, a 0.46% decline from fiscal 2022.
- Aquestive Therapeutics, Inc. operating lease, cost for fiscal 2022 was $1.75M, a 1.62% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 9 month as first filed | Operating Lease, Cost 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $558.00K 10-Q · filed 2026-08-11 | $1.01M 10-Q · filed 2026-08-11 | $1.45M derived: sum of 3 quarters · filed 2026-08-11 | $1.90M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $447.00K 10-Q · filed 2026-05-13 | $895.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.35M derived: sum of 3 quarters · filed 2026-05-13 | $1.80M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-12-31 | $448.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $899.00K derived: sum of 2 quarters · filed 2026-03-04 | $1.36M derived: sum of 3 quarters · filed 2026-08-11 | $1.78M 10-K · filed 2026-03-04 | ||
| 2025-09-30 | $451.00K 10-Q · filed 2025-11-05 | $908.00K derived: sum of 2 quarters · filed 2026-08-11 | $1.33M 10-Q · filed 2025-11-05 | $1.80M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-06-30 | $457.00K 10-Q · filed 2026-08-11 | $884.00K 10-Q · filed 2026-08-11 | $1.35M derived: sum of 3 quarters · filed 2026-08-11 | $1.81M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $427.00K 10-Q · filed 2026-05-13 | $896.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.35M derived: sum of 3 quarters · filed 2026-05-13 | $1.80M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $469.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $926.00K derived: sum of 2 quarters · filed 2026-03-04 | $1.37M derived: sum of 3 quarters · filed 2026-03-04 | $1.81M 10-K · filed 2026-03-04 | ||
| 2024-09-30 | $457.00K 10-Q · filed 2025-11-05 | $901.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.34M 10-Q · filed 2025-11-05 | $1.78M derived: sum of 4 quarters · filed 2025-11-05 | ||
| 2024-06-30 | $444.00K 10-Q · filed 2025-08-11 | $888.00K 10-Q · filed 2025-08-11 | $1.32M derived: sum of 3 quarters · filed 2025-08-11 | $1.76M derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2024-03-31 | $444.00K 10-Q · filed 2025-05-12 | $881.00K derived: sum of 2 quarters · filed 2025-05-12 | $1.32M derived: sum of 3 quarters · filed 2025-05-12 | $1.77M derived: sum of 4 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $437.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $875.00K derived: sum of 2 quarters · filed 2025-03-05 | $1.33M derived: sum of 3 quarters · filed 2025-03-05 | $1.75M 10-K · filed 2025-03-05 | ||
| 2023-09-30 | $438.00K 10-Q · filed 2024-11-04 | $890.00K derived: sum of 2 quarters · filed 2024-11-04 | $1.31M 10-Q · filed 2024-11-04 | $1.79M derived: sum of 4 quarters · filed 2024-11-04 | ||
| 2023-06-30 | $452.00K 10-Q · filed 2024-08-06 | $870.00K 10-Q · filed 2024-08-06 | $1.36M derived: sum of 3 quarters · filed 2024-08-06 | $1.78M derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $418.00K 10-Q · filed 2024-05-07 | $904.00K derived: sum of 2 quarters · filed 2024-05-07 | $1.33M derived: sum of 3 quarters · filed 2024-05-07 | $1.75M derived: sum of 4 quarters · filed 2024-05-07 | ||
| 2022-12-31 | $486.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $910.00K derived: sum of 2 quarters · filed 2024-03-05 | $1.33M derived: sum of 3 quarters · filed 2024-03-05 | $1.75M 10-K · filed 2024-03-05 | ||
| 2022-09-30 | $424.00K 10-Q · filed 2023-11-06 | $848.00K derived: sum of 2 quarters · filed 2023-11-06 | $1.27M 10-Q · filed 2023-11-06 | $1.70M derived: sum of 4 quarters · filed 2023-11-06 | ||
| 2022-06-30 | $424.00K 10-Q · filed 2023-08-07 | $843.00K 10-Q · filed 2023-08-07 | $1.27M derived: sum of 3 quarters · filed 2023-08-07 | $1.71M derived: sum of 4 quarters · filed 2023-08-07 | ||
| 2022-03-31 | $419.00K 10-Q · filed 2023-05-02 | $850.00K derived: sum of 2 quarters · filed 2023-05-02 | $1.28M derived: sum of 3 quarters · filed 2023-05-02 | $1.71M derived: sum of 4 quarters · filed 2023-05-02 | ||
| 2021-12-31 | $431.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $862.00K derived: sum of 2 quarters · filed 2023-03-31 | $1.29M derived: sum of 3 quarters · filed 2023-03-31 | $1.73M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $431.00K 10-Q · filed 2022-11-01 | $861.00K derived: sum of 2 quarters · filed 2022-11-01 | $1.29M 10-Q · filed 2022-11-01 | $2.15M derived: sum of 4 quarters · filed 2022-11-01 | ||
| 2021-06-30 | $430.00K 10-Q · filed 2022-08-02 | $863.00K 10-Q · filed 2022-08-02 | $1.72M derived: sum of 3 quarters · filed 2022-08-02 | $2.09M derived: sum of 4 quarters · filed 2022-08-02 | ||
| 2021-03-31 | $433.00K 10-Q · filed 2022-05-04 | $1.28M derived: sum of 2 quarters · filed 2022-05-04 | $1.66M derived: sum of 3 quarters · filed 2022-05-04 | $2.04M derived: sum of 4 quarters · filed 2022-05-04 | ||
| 2020-12-31 | $852.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $1.23M derived: sum of 2 quarters · filed 2022-03-08 | $1.61M derived: sum of 3 quarters · filed 2022-03-08 | $1.67M 10-K · filed 2022-03-08 | ||
| 2020-09-30 | $377.00K 10-Q · filed 2021-11-02 | $409.00K 10-Q · filed 2020-11-04 | $754.00K derived: sum of 2 quarters · filed 2021-11-02 | $819.00K 10-Q · filed 2021-11-02 | $1.23M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $377.00K 10-Q · filed 2021-08-03 | $819.00K 10-Q · filed 2021-08-03 | ||||
| 2020-03-31 | $442.00K 10-Q · filed 2021-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |